BUZZ-Exact Sciences falls after company cuts 2024 revenue forecast

Reuters

Nov 06, 2024

** Shares of cancer test maker Exact Sciences fall 27.3% to $52 after the bell

** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln

** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG

** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln

** "Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong" - EXAS

** Up to last close, share are down 3.3% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481654838"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481654838\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481654838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481654838","market":"us","top_or_hot":-1,"title":"BUZZ-Exact Sciences falls after company cuts 2024 revenue forecast","media":"Reuters","content":"<html><body><p>** Shares of cancer test maker Exact Sciences    fall 27.3% to $52 after the bell  </p><p>   ** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln</p><p>   ** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG </p><p>   ** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln</p><p>   ** \"Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong\" - EXAS </p><p>   ** Up to last close, share are down 3.3% YTD </p><p> (Reporting by Sneha S K)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Exact Sciences falls after company cuts 2024 revenue forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Exact Sciences falls after company cuts 2024 revenue forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-06 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Shares of cancer test maker Exact Sciences    fall 27.3% to $52 after the bell  </p><p>   ** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln</p><p>   ** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG </p><p>   ** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln</p><p>   ** \"Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong\" - EXAS </p><p>   ** Up to last close, share are down 3.3% YTD </p><p> (Reporting by Sneha S K)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481654838","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481654838","pubTimestamp":1730842615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of cancer test maker Exact Sciences    fall 27.3% to $52 after the bell     ** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln   ** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG    ** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln   ** \"Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong\" - EXAS    ** Up to last close, share are down 3.3% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学"},"translate_title":"BUZZ-Exact Sciences下调2024年收入预测后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1},"content_text":"** Shares of cancer test maker Exact Sciences    fall 27.3% to $52 after the bell     ** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln   ** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG    ** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln   ** \"Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong\" - EXAS    ** Up to last close, share are down 3.3% YTD  (Reporting by Sneha S K)((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}